

## **I. KEY FACTS OVER THE PERIOD**

- Results and Cash burn in line with expectations
- Cash position of € 31M as of June 30<sup>th</sup>, 2015
- Resignation of Pierre-Olivier GOINEAU, co-founder & Deputy Chief Executive Officer on January 11, 2015
- ERYTECH initiated a Level 1 ADR program in U.S. and announced plans to conduct a registered initial public offering in the United States
- ERYTECH presented 3 posters at the American Association for Cancer Research (AACR) Annual Meeting from April 18 to 22, 2015 in Philadelphia (United States), including an oral presentation of the full Grasp<sup>®</sup> phase III clinical trial for patients with ALL and also an overview of the phase IIb for patients with AML.
- IP portfolio reinforced in the United States with a newly granted patent and also the extension of the patent term protection, for its patent entitled “*Medicament for the Treatment of Cancer of the Pancreas*” which was issued by the U.S. Patent and Trademark Office (USPTO) as U.S. Patent No. 8974802
- The Company received the EnterNext Tech 40 label and announced that it was admitted into the Tech 40 index
- ERYTECH announced that its independent data safety monitoring board (DSMB) has conducted the first tolerance analysis of its Expanded Access Program in the ALL and has recommended to continue the enrollment of patients in the EAP without changes to the protocol
- ERYTECH announces two positive safety reviews after the completion of the first cohort in the Company’s US Phase I study with ERY-ASP in Acute Lymphoblastic Leukemia (ALL), and following the treatment of the first three patients with ERY-ASP in combination with Folfox in its Phase II study in pancreatic cancer
- ERYTECH announced the appointment of Iman El-Hariry as Chief Medical Officer, responsible for global medical, clinical and regulatory affairs
- ERYTECH announced the appointment of Eric Soyer as Chief Financial and Chief Operating Officer (CFO/COO) as a replacement for Pierre-Olivier GOINEAU

## II. ACTIVITY REPORT

### A. Company's situation and results from activities

#### a. Clinical Trials

##### ➤ GRASPA® in Europe (ERY-ASP)

The Data and Safety Monitoring Board, or DSMB, in charge of monitoring the Phase II / III clinical trial of GRASPA® in relapsed adults and children with ALL met and issued a favourable opinion related to the conduct of this phase III clinical trial according to the original protocol with a total of 80 patients. Based on the results of the completed clinical trials in ALL Phase III, the Company plans to submit a Marketing Authorization Application before the EMA in the second half of 2015.

The European Union has granted GRASPA® an orphan drug designation in the AML.

The Company received the authorization from ANSM (French Medicine Agency) to begin a Phase II B clinical trial in AML. The first patient was enrolled in March.

The independent Data and Safety Monitoring Board (DSMB) in charge of the safety assessment of the Company's Phase IIb study of GRASPA® in Acute Myeloid Leukemia (AML), and after the first positive analysis on the first 30 patients, recommended continuation of the trial without modification.

The Company received the authorization from several European countries for the AML clinical study allowing the enrollment of a larger number of patients.

The Company announced the launch of a Phase 2 clinical trial of ERY-ASP™ for patients with pancreatic cancer.

The Company announced the addition of a new product development candidate, ERY-MET, to the Company's "tumor starvation" dedicated oncology product pipeline.

##### ➤ ERY-ASP in the United States

The Company received the authorization from The United States Food and Drug Administration (FDA) to initiate a Phase Ib clinical trial of its product ERY-ASP®, in the ALL. The principal patient recruitment centers opened are: Chicago, Duke, Columbus.

The US patent office (USPTO) issued a patent protecting ERYTECH's technology in the USA with an exclusivity term until 2029, which can be further extended to 2034.

Internationally, a new U.S. patent was issued to the Company.

#### b. Research & Development

##### ➤ TEDAC

Erytech has led different experiences over various tumor types testing their sensitivity to L-Asparaginase with the objective to launch a Phase II clinical trial in solid cancer. The induced study results would lead to the selection of a first therapeutic indication in which there will be a Phase II clinical study.

Other trials with other therapeutic enzymes are being conducted following the defined step-plan. The objective to develop a group of products capable of inducing tumor starvation combined with the selection of patients is taking form. The first proof-of-concept on tumor sections are underway. By maintaining the speed of development, and subject to positive results, a first clinical trial could be considered at the very end of 2015.

As of June 30, 2015, the TEDAC program has reached key step n°3 which will allow the Company to qualify for a new portion of the subsidies granted on this program.

➤ Other on-going projects

Alongside the development of ERY-ASP/GRASPA®, Erytech has conducted extensive research to identify additional therapeutic enzymes that could induce tumor starvation and whose encapsulation in red blood cells would be relevant. The Company has received a € 7M funding from BPI France for this research program.

This research program enabled the Company to identify a new drug candidate, ERY-MET, which consists of methionine- $\gamma$ -lyase (MGL) encapsulated in red blood cells.

In addition to the use of our ERYCAPS platform to encapsulate enzymes to increase their circulating activity and reduce their toxicity, Erytech believes that it can expand the use of its ERYCAPS technology to develop cancer vaccines.

### c. Industrial Property

As at June 30, 2015, Erytech owns 12 patent families, in France and in the rest of the world. The Company also has a license from the U.S. National Institutes of Health (USA) on the rights to a diagnostic method in order to determine the effectiveness of L. Asparaginase in a patient.

### d. Employees

As at June 30, 2015, the Company has 45 full-time employees.

### e. Finance

#### Comparisons for the Six-Month Periods Ended June 30, 2014 and 2015

##### *Operating Income*

We generated operating income of €1,474,406 and €721,980 in the six-month periods ended June 30, 2015 and 2014, respectively, an increase of 104.2%.

The components of our operating income are set forth in the table below. Other income was primarily generated by the CIR and by subsidies received from BPI France for our research projects.

	<b>FOR THE SIX-MONTH PERIOD ENDED JUNE 30,</b>	
	<b>2015</b>	<b>2014</b>
Revenues	€ -	€ -
Other income		
- Research Tax Credit	1,092,097	607,390
- Subsidies	270,440	99,876
- Other income	111,869	14,713
<b>Total Operating Income</b>	<b>1,474,406</b>	<b>721,980</b>

As no research and development expenditure is capitalized before obtaining a marketing authorization, the CIR related to a research program is entirely recognized as operating income.

The amounts recognized as CIR income represents the expected reimbursement of 30% of qualifying costs incurred by us. The increase in CIR income for the six-month period ended June 30, 2015 compared to the six-month period ended June 30, 2014 is the result of increased costs we incurred in relation to our research projects.

Grants recorded in operating income represent non-reimbursable subsidies. The amounts recorded for the six-month periods ended June 30, 2014 and 2015 relate to grants associated with the TEDAC programs in partnership with BPI France.

Other income totaled €14,713 and €111,869 for the six-month periods ended June 30, 2014 and 2015 respectively. The amount for 2015 represents the sum of internal costs borne by us within the context of the AML study and re-invoiced to Orphan Europe.

#### *Research and Development Expenses*

The total amount recorded by us for research and development activities increased from €1,913,985 for the six-month period ended June 30, 2014 to €5,231,340 for the six-month period ended June 30, 2015, an increase of 173.3%.

Our research and development expenses are broken down by nature in the table below:

	<b>FOR THE SIX-MONTH PERIOD ENDED JUNE 30,</b>		
	<b>2015</b>	<b>2014</b>	<b>% CHANG E</b>
ERY-ASP	868,010	206,051	321%
TEDAC (ERY-MET / ERY-ADI)	545,111	115,940	370%
<b>Total direct research and development expenses</b>	<b>1,413,121</b>	<b>321,991</b>	<b>339%</b>
Consumables	360,610	142,777	153%
Rental and maintenance	216,316	147,989	46%
Services, subcontracting, and consulting fees	1,049,384	429,361	144%
Personnel expenses <sup>(1)</sup>	2,053,387	743,039	176%
Depreciation and amortization expense	114,841	101,225	13%
Other	23,680	27,603	-14%
<b>Total indirect research and development expenses</b>	<b>3,818,218</b>	<b>1,591,994</b>	<b>140%</b>
<b>Total R&amp;D expenses<sup>(2)</sup></b>	<b>€5,231,339</b>	<b>€1,913,985</b>	<b>173%</b>

<sup>(1)</sup> Includes €0 and €657,803 related to the share-based compensation expense for the six-month periods ended June 30, 2014 and 2015, respectively.

<sup>(2)</sup> Of which €766,993 and €3,253,081 related to clinical studies for the six-month periods ended June 30, 2014 and 2015, respectively.

The increase in total research and development expenditures for the six-month period ended June 30, 2014 compared to the six-month period ended June 30, 2015 was primarily the result of a €620,023 increase in third-party services, subcontracting and consulting fees paid to CROs and other service providers for our manufacturing and clinical trials conducted in the first half of 2015 and a €1,310,348 increase in personnel expenses due to increasing headcount and share-based compensation issued to research and development personnel. We also experienced a €217,233 increase in consumables, which was primarily the result of increased purchases of clinical products such as enzyme and blood samples for use in clinical development. We have also experienced a €1,091,130 increase in direct research and development expenses related to ERY-ASP, namely as a result of clinical trials performed in relation to pancreatic cancer and TEDAC, which is expected to continue in future periods given our intention to commence a Phase 1 clinical trial of ERY-MET in 2016.

### General and Administrative Expenses

Our general and administrative expenses increased from €1,991,388 for the six-month period ended June 30, 2014 to €3,106,512 for the six-month period ended June 30, 2015, an increase of 56%. The increase of €1,115,124 in general and administrative expenses was primarily due to an increase of €627,563 in services, subcontracting, and fees, associated with the development of our regulatory and commercialization strategy in the United States, as well as consulting fees and third-party fees in connection with the recruitment of our Chief Medical Officer and Chief Financial Officer in 2015. We also experienced an increase of €558,265 in other costs, primarily the result of share-based warrants issued to board members.

Our general and administrative expenses are broken down by nature as follows:

FOR THE SIX-MONTH PERIOD ENDED JUNE 30,			
	2015	2014	% CHANGE
Consumables	€ 37,029	€ 15,042	146%
Rental and maintenance	196,984	201,540	-2%
Services, subcontracting, and consulting fees	1,123,995	496,432	126%
Personnel expenses <sup>(1)</sup>	507,665	682,211	-26%
Depreciation and amortization expense	99,122	12,720	679%
Other <sup>(2)</sup>	1,141,718	583,443	96%
<b>Total general and administrative expenses</b>	<b>€3,106,512</b>	<b>€1,991,388</b>	<b>56%</b>

<sup>(1)</sup> Includes €79,488 and €643,599 related to the share-based compensation expense for the six-month periods ended June 30, 2014 and 2015, respectively.

<sup>(2)</sup> Includes €0 and €512,010 related to the share-based compensation expense to directors for the six-month periods ended June 30, 2014 and 2015, respectively.

### Financial Income (Loss)

Our net financial income increased by €321,568 in the six-month period ended June 30, 2015 compared to the six-month period ended June 30, 2014 and is broken down as follows:

FOR THE SIX-MONTH PERIOD ENDED JUNE 30,		
	2015	2014
Financial expense	€(17,937)	€(33,839)
Financial income	343,015	37,349
<b>Net financial income (loss)</b>	<b>€325,078</b>	<b>€3,510</b>

The increase is primarily due to interest income earned on interest-bearing accounts. The increase is due to the investment of the amounts raised during the capital raise on the Euronext market in October 2014.

### Cash Flows

FOR THE SIX-MONTH PERIOD ENDED JUNE 30,		
	2015	2014
Net cash flows used in operating activities	€(5,956,904)	€(3,306,518)

Net cash flows used in investing activities	(46,694)	(161,919)
Net cash flows from financing activities	61,583	641,437
<b>Net decrease in cash and cash equivalents</b>	<b>€(5,942,015)</b>	<b>€(2,827,000)</b>

Our net cash flows used in operating activities were €3,306,518 and €5,956,904 in the first halves of 2014 and 2015, respectively. For the six-month period ended June 30, 2015, our net cash flows used in operating activities increased due to our continued efforts in advancing our research and development programs such as TEDAC as well as increased general and administrative expenses.

Our net cash used in investing activities were €161,919 and €46,694 in 2014 and 2015, respectively. This decrease mainly reflects the fact that our investments in relation to acquiring property and plant equipment for our headquarters in Lyon are now fully completed.

Our net cash flows from financing activities decreased from €641,437 in 2014 to €61,583 in 2015 as a result of the decrease in the number of treasury shares held within the scope of the liquidity agreement.

## **B. Forecasts**

The second half of 2015 will be a major semester regarding the clinical developments with:

- i. The filing of the Marketing Authorization Application (MAA)
- ii. The on-going clinical study and final patients' enrollment in the AML
- iii. The continuation of patient enrollment in the United States for the ALL clinical study with the use of ERY-ASP for adult patients

## **C. Major events happening from July 1, 2015, to the publication of this report**

On July 20, 2015, the Company announced a positive DSMB safety review following the treatment of the first twenty-four patients with ERY-ASP in its Phase 2 study in pancreatic cancer.

## **D. Information concerning related parties**

Relations with related parties during the first half of 2014 are available in the notes to interim condensed consolidated statements issued in compliance with IAS 34 hereafter.

## **E. Risks & Uncertainties**

All risks and uncertainties likely to have a material effect on the company's financial situation and results are presented in the company's Prospectus, which received the visa of the French *Autorité des Marchés Financiers* on June 4, 2015, under the number R.15-048.

Over the period, no changes in the Risk Factors have occurred, neither in their nature nor in their form, and at the date of the publication of this report no other risks nor uncertainties exist for the previous six months of the financial year.

**III. INTERIM CONDENSED CONSOLIDATED STATEMENTS FOR THE SIX-MONTH PERIOD ENDED JUNE 30, 2015**

**CONSOLIDATED STATEMENTS OF NET INCOME (LOSS) AND CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)**

	Notes	SIX MONTHS ENDED JUNE 30,	
		2015	2014
		€	€
Revenues.....			
Other income .....	4.1	1,474,406	721,980
<b>Total operating income.....</b>		<b>1,474,406</b>	<b>721,980</b>
<b>Operating expenses</b>			
Research and development.....	4.2 to 4.3	(5,231,340)	(1,913,985)
General and administrative .....	4.2 to 4.3	(3,106,512)	(1,991,388)
<b>Operating loss.....</b>		<b>(6,863,446)</b>	<b>(3,183,393)</b>
Financial income.....	4.5	343,015	37,349
Financial expenses .....	4.5	(17,937)	(33,839)
<b>Financial income (loss) .....</b>		<b>325,078</b>	<b>3,510</b>
<b>Pre-tax income (loss).....</b>		<b>6,538,368</b>	<b>3,179,883</b>
Income tax .....		5,142	(4,173)
<b>Net loss .....</b>		<b>(6,533,226)</b>	<b>(3,184,056)</b>
<b>Elements that may be reclassified subsequently to income (loss).....</b>			
None			
<b>Elements that may not be reclassified subsequently to income (loss) ...</b>			
Remeasurement of defined benefit liability (asset) .....		16,698	(12,121)
Tax effect.....		(5,749)	4,173
<b>Other comprehensive income.....</b>		<b>10,949</b>	<b>(7,948)</b>
<b>Total comprehensive loss.....</b>		<b>(6,522,277)</b>	<b>(3,192,004)</b>
Basic / diluted loss per share (€/share).....		(0.95)	(0.57)

## CONSOLIDATED STATEMENTS OF FINANCIAL POSITIONS

	Notes	AS OF	
		JUNE 30, 2015	DECEMBER 31, 2014
		€	€
<b>ASSETS</b>			
<b>Non-current assets</b>			
Intangible assets .....	5.1	44,115	30,951
Property, plant and equipment, net .....	5.1	860,071	967,474
Other non-current financial assets .....	5.1	89,784	81,814
Deferred tax assets			
<b>Total non-current assets</b> .....		<b>993,970</b>	<b>1,080,239</b>
<b>Current assets</b>			
Inventories .....		184,622	198,356
Trade and other receivables.....	5.2	266,648	104,870
Other current assets .....	5.3	3,609,109	2,234,738
Cash and cash equivalents.....	5.4	31,046,421	36,988,436
<b>Total current assets</b> .....		<b>35,106,800</b>	<b>39,526,400</b>
<b>TOTAL ASSETS</b> .....		<b>36,100,770</b>	<b>40,606,639</b>
<b>LIABILITIES AND SHAREHOLDERS' EQUITY</b>			
<b>Shareholder's equity</b> .....			
Share capital.....	5.5	688,679	688,276
Premiums related to the share capital .....	5.5	72,538,487	72,426,817
Reserves .....	5.5	(35,978,441)	(28,430,754)
Net loss for the period .....		(6,533,226)	(8,860,036)
<b>Total shareholders' equity</b> .....		<b>30,715,498</b>	<b>35,824,303</b>
<b>Non-current liabilities</b>			
Long-term provisions .....	5.6	91,946	88,594
Financial liabilities—non-current portion .....	5.7	144,459	436,035
Deferred tax liabilities			
Other non-current liabilities			
<b>Total non-current liabilities</b> .....		<b>236,406</b>	<b>524,629</b>
<b>Current liabilities</b>			
Short-term provisions			
Financial liabilities—current portion.....	5.7	575,660	333,502
Trade and other payables.....		3,840,222	2,084,546
Other current liabilities.....	65.8	732,983	1,839,658
<b>Total current liabilities</b> .....		<b>5,148,865</b>	<b>4,257,706</b>
<b>TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY</b> ....		<b>36,100,770</b>	<b>40,606,639</b>

## CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY

(Amounts in euros)

	SHARE CAPITAL	PREMIUMS RELATED TO THE SHARE CAPITAL	RESERVES	INCOME (LOSS)	TOTAL SHAREHOLDERS' EQUITY
<b>At December 31, 2013</b> .....	<b>550,602</b>	<b>42,741,059</b>	<b>(21,560,305)</b>	<b>(8,144,721)</b>	<b>13,586,634</b>
Issue of ordinary shares .....	762				762
Share premium increase .....		55,336			55,336
Treasury shares .....	4,704	644,275			648,980
Allocation of prior period loss .....			(8,144,721)	8,144,721	
Net loss .....				(3,184,056)	(3,184,056)
Actuarial gain (loss) .....			(7,948)		(7,948)
IFRS 2 expenses .....			79,488		79,488
<b>At June 30, 2014</b> .....	<b>556,068</b>	<b>43,440,671</b>	<b>(29,633,486)</b>	<b>(3,184,056)</b>	<b>11,179,196</b>
<b>At January 1, 2015</b> .....	<b>688,276</b>	<b>72,426,817</b>	<b>(28,430,754)</b>	<b>(8,860,036)</b>	<b>35,824,303</b>
Issue of ordinary shares .....	653				653
Share premium increase .....		47,421			47,421
Treasury shares .....	(250)	64,250			64,000
Allocation of prior period loss .....			(8,860,036)	8,860,036	
Net loss .....				(6,533,226)	(6,533,226)
Actuarial gain/(loss) .....			10,949		10,949
IFRS 2 expenses .....			1,301,402		1,301,402
<b>At June 30, 2015</b> .....	<b>688,679</b>	<b>72,538,487</b>	<b>(35,978,441)</b>	<b>(6,533,226)</b>	<b>30,715,498</b>

## CONSOLIDATED STATEMENTS OF CASH FLOW

	Notes	SIX MONTHS ENDED JUNE 30	
		2015	2014
		€	€
<b>Net loss</b> .....		(6,533,226)	(3,184,056)
Expenses (income) with non-cash impact			
Amortization and depreciation .....		132,963	113,945
Increase in long-term provisions .....		18,122	25,196
Expense related to share-based payments .....		1,301,402	79,488
Interest expense .....		2,392	25,750
Income tax expense (due and deferred) .....		(5,142)	4,173
<b>Operating cash flow before change in working capital</b> .....		<b>(5,083,489)</b>	<b>(2,935,504)</b>
Increase/decrease in inventories .....		13,735	(21,645)
Increase in trade and other receivables .....		(161,778)	(19,622)
Increase/decrease in other current assets .....		(1,374,373)	305,357
Increase in trade and other payables .....		1,755,676	18,958
Decrease in other current liabilities .....		(1,106,675)	(654,062)
<b>Change in working capital</b> .....		<b>(873,415)</b>	<b>(371,014)</b>
<b>Net cash flow used in operating activities</b> .....		<b>(5,956,904)</b>	<b>(3,306,518)</b>
<b>Cash flows from investing activities:</b>			
Acquisition of property, plant and equipment		(20,850)	(154,340)
Acquisitions of intangible assets .....		(18,644)	(8,777)
Acquisition of other non-current financial assets .....		(7,200)	—
Disposal of property, plant and equipment			
Disposal of intangible assets			
Disposal of non-current financial assets .....		—	1,197
<b>Net cash flow used in investing activities</b> .....		<b>(46,694)</b>	<b>(161,919)</b>
<b>Cash flows from financing activities:</b>			
Capital increases, net of transaction costs .....		48,074	56,098
Proceeds from borrowings .....		—	—
Costs of borrowings			
Repayment of borrowings .....		(50,489)	(63,641)
Treasury shares .....		63,998	648,980
<b>Net cash flow from financing activities</b> .....		<b>61,583</b>	<b>641,437</b>
<b>Decrease in cash and cash equivalents</b> .....		<b>(5,942,015)</b>	<b>(2,827,000)</b>
Cash and cash equivalents at the beginning of the period .....		36,988,436	15,112,523
Cash and cash equivalents at the close of the period .....		31,046,421	12,285,523
<b>Net Decrease in cash and cash equivalents</b> .....		<b>(5,942,015)</b>	<b>(2,827,000)</b>
<b>Supplemental disclosure of cash flows information:</b>			
Cash paid for interest .....		15,545	7,738

#### IV. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

The notes are an integral part of accompanying interim consolidated financial statements as of June, 30, 2015. The financial statements were approved by the Board of Directors on September 8, 2015.

The Group comprises the parent company, Erytech Pharma S.A., and a wholly owned subsidiary located in the United States, Erytech Pharma Inc.

##### I. Description of the company's business

The main activity of the Company is research and development in the treatment of acute leukemia and other orphan diseases.

Since its inception, the Company has focused on:

- The development of a patented technology based on the encapsulation of molecules into red blood cells, offering an innovative approach to the treatment of acute leukemia and other solid tumors. The development of the main product, Graspas®, initiated at the inception of the Company resulted in the issuance of 12 patent families held in its own name. The Company also developed a patented industrial process capable of producing clinical batches of Graspas®, and able to meet demand when the products are commercialized.
- The implementation of clinical programs in order to validate Graspas® initially in terms of safety of use and toxicology through a phase I clinical study in acute lymphoblastic leukemia (ALL) in adult and pediatric patients with relapsed LAL. Based on the results obtained, the Company completed a clinical Phase II study which also demonstrated the safety of use and efficacy of the products in more than 55 patients in ALL. The Company has completed a Phase III clinical trial at the end of which Erytech plans to file a marketing approval application in Europe for Graspas® in the LAL. The Company has also initiated a Phase II study in acute myeloid leukemia (AML).

The business model of the Company is to develop its products until it obtains a marketing approval in Europe then in the United States. Commercial partnerships concluded by Erytech will ensure the distribution of Graspas® in Europe first and then in the United States and the rest of the world. Erytech has the capacity to manufacture products for the sales of Graspas® during the first years of commercialization in Europe through its production unit in Lyon.

##### II. Major events of the period

Pierre-Olivier Goineau, co-founder of the Company and Deputy Chief Executive Officer, resigned from his positions during the Company's Board of Directors meeting held on January 11, 2015. Pierre-Olivier Goineau remains treasurer and secretary of the Company's U.S. subsidiary, ERYTECH Pharma, Inc.

Iman El-Hariry joined the Company as Chief Medical Officer of the Company's subsidiary, ERYTECH Pharma, Inc., located in Boston, and will be responsible for medical, clinical and regulatory affairs.

During the six-month period ended June 30, 2015, additional warrants (*bons de souscription d'actions*) have been allocated as follows (see note 4.3):

- The Board of Directors meeting held on April 29, 2015 allocated 2,150 BSA2012 to independent members of the Board of Directors;

- In accordance with the 2014 Plan, the Board of Directors meeting held on June 23, 2015 allocated the first tranche of the plan and granted 2,500 BSPCE2014 to a category of Erytech employees with management status and 3,000 BSA2014 to Dr. El-Hariry working for the Company's subsidiary, ERYTECH Pharma, Inc., located in the United States.

Finally, the Company has not received the research tax credit (*Crédit d'Impôt Recherche* or "CIR") for 2014 as of June 30, 2015 for an amount of €1,523,688; the receivables in the balance sheet as of June 30, 2015 therefore correspond to the research tax credit of the six-month period ended June 30, 2015 and the balance for 2014.

### III. Significant accounting policies and methods

According to European regulation 1606/2002 dated July 19, 2002, the consolidated financial statements of the company are prepared in accordance with IFRS (International Financial Reporting Standards) published by the IASB (International Accounting Standards Board) as adopted by the European Union on June 30, 2015.

These standards are available on the European Commission website at the following address ([http://ec.europa.eu/internal\\_market/accounting/ias/index\\_fr.html](http://ec.europa.eu/internal_market/accounting/ias/index_fr.html)).

The interim financial statements, presented in a summary form, have been prepared in accordance with International Financial Reporting Standard IAS 34 ("Interim Financial Reporting").

The interim financial statements do not include all information and notes as presented in the annual financial statements. Therefore, they must be read in conjunction with the financial statements of the Company as of December 31, 2014.

The financial statements are presented in euros which is the functional currency of the Company. All amounts mentioned in the notes to the financial statements are expressed in euros unless otherwise indicated.

Except for the standards applicable as of January 1, 2015 described below, the accounting policies and methods applied in the preparation of interim financial statements are the same as those applied to prepare the financial statements as of December 31, 2014.

#### **Standards, amendments and interpretations effective within the European Union from the period beginning on January 1, 2015**

The Group has adopted the following standards, amendments and interpretations applicable as of January 1, 2015:

- IFRIC 21: "Duties and taxes": this interpretation clarifies that tax must be accounted for in accordance with their triggering event as defined by the law regardless of their cost bases. The application of this standard has no effect on the annual financial statements.
- Amendments to IAS 16 (property, plant and equipment) and IAS 38 (Intangible assets) on acceptable depreciation methods. The IASB has indicated that using an amortization method based on revenues is not appropriate because it does not reflect the consumption of economic benefits of an intangible asset. This presumption can be rebutted in certain circumstances.
- Amendments to IFRS 11 "Joint Arrangements" concerning the acquisition of an interest in a joint venture;
- Amendments to IAS 19 "employee benefits" that applies to contributions by staff members or third parties to define benefit plans. Some contributions can now be deducted from the service cost in the period in which the service is provided;

- Annual Improvements to IFRS (December 2013) applicable as of July 1, 2014: these amendments relate mainly to the information on related parties (IAS 24), more specifically clarifications on the concept of performance provided by the "key" staff members of the management, the share-based payments (IFRS 2), including a clarification of the concept of "vesting conditions", segment reporting (IFRS 8) and the information to be provided on grouping criteria and the reconciliation of assets by segment with all the assets of the entity, clarification of the concept of fair value for receivables and short-term debt and the possibility of offsetting of financial assets and liabilities (IFRS 13 fair value) and, the recognition of contingent consideration in business combinations (IFRS 3).

These new texts have had no material impact on the results and financial position of the group. The standards and interpretations of optional application as of June 30, 2015 have not been applied in advance. However, the group does not anticipate significant impacts related to the implementation of these new texts.

### **Presentation**

The statements of income (loss) classify expenses and income by function.

The comparative information is presented using an identical classification.

The statements of cash flows were prepared according to the indirect method.

The financial statements are prepared in accordance with the accounting principles of going concern and the permanence of accounting methods.

### **Use of estimates**

Preparation of the financial statements in accordance with the rules prescribed by the IFRS requires the use of estimates and the formulation of hypothesis having an impact on the financial statements. These estimates can be revised where the circumstances on which they are based change. The actual results may therefore differ from the estimates initially formulated. The main estimates used are described in the annual financial reports.

### **Segment reporting**

In accordance with IFRS 8 Operating Segments, reporting by operating segment is derived from the internal organization of the Company's activities; it reflects management's viewpoint and is established based on internal reporting used by the chief operating decision maker (the Chairman—CEO) to allocate resources and to assess performance.

The current reporting of the company has identified a single operating segment.

The operating segment is subject to individual monitoring for internal reporting purposes, according to performance indicators.

#### IV. Notes related to the consolidated statements of net income (loss)

##### 4.1 Other operating income

Other operating income consists in the following:

(Amounts in euros)	FOR THE SIX-MONTH PERIOD ENDED JUNE 30,	
	2015	2014
Research Tax Credit	1,092,097	607,390
Subsidies	270,440	99,876
Other income	111,869	14,713
<b>Other operating income</b>	<b>1,474,406</b>	<b>721,980</b>

The operating income is primarily generated by the CIR research tax credit, and the subsidies associated with the pre-clinical research programs in partnership with BPI France.

Other income totaled €14,713 and €111,869 for the six-month periods ended June 2014 and June 2015, respectively. For the six-month period ended June 30, 2015, the other income represents the recharge to Orphan Europe of the internal costs borne by the Company within the context of the AML study in 2015.

The increase in the research tax credit and the grants for the six-month period ended June 30, 2015 compared to the same period in 2014 is due to the increased research and development activity over the two periods.

## 4.2 Operating expenses by nature

FOR THE SIX MONTH PERIOD ENDED JUNE 30, 2015 (Amounts in euros)	OTHER R&D EXPENSES	CLINICAL STUDIES	INTELLECTUAL PROPERTY	RESEARCH AND DEVELOPMENT EXPENSES	GENERAL AND ADMINISTRATIVE EXPENSES	TOTAL
Consumables.....	149,485	353,260	—	502,745	37,029	539,774
Rental and maintenance .....	110,638	158,283	—	268,921	196,984	465,905
Services, subcontracting, and fees.....	612,608	1,201,881	205,577	2,020,066	1,123,995	3,144,061
Personnel expenses .....	805,296	1,197,987	50,104	2,053,387	507,665	2,561,052
Other.....	29,824	240,443	1,112	271,379	1,141,718	1,413,097
Depreciation and amortization expense	13,614	101,227	—	114,841	99,122	213,963
<b>Total.....</b>	<b>1,721,465</b>	<b>3,253,081</b>	<b>256,793</b>	<b>5,231,340</b>	<b>3,106,512</b>	<b>8,337,852</b>

FOR THE SIX MONTH PERIOD ENDED JUNE 30, 2014 (Amounts in euros)	OTHER R&D EXPENSES	CLINICAL STUDIES	INTELLECTUAL PROPERTY	RESEARCH AND DEVELOPMENT EXPENSES	GENERAL AND ADMINISTRATIVE EXPENSES	TOTAL
Consumables.....	162,532	40,654	—	203,186	15,042	218,228
Rental and maintenance .....	69,186	80,626	—	149,812	201,540	351,352
Services, subcontracting, and fees	220,513	246,749	173,611	640,873	496,432	1,137,305
Personnel expenses .....	460,398	249,979	32,662	743,039	682,211	1,425,250
Other.....	11,713	64,137	—	75,850	583,443	659,293
Depreciation and amortization expense	16,377	84,848	—	101,225	12,720	113,945
<b>Total.....</b>	<b>940,719</b>	<b>766,993</b>	<b>206,273</b>	<b>1,913,985</b>	<b>1,991,388</b>	<b>3,905,373</b>

The increase in the “other” caption is due to the granting of BSA2012 to members of the board of directors for an amount of €512,010.

## 4.3 Personal expenses

The personal expenses are broken down as follows:

FOR THE SIX MONTH PERIOD ENDED JUNE 30, 2015 (Amounts in euros)	OTHER R&D EXPENSES	CLINICAL STUDIES	INTELLECTUAL PROPERTY	GENERAL AND ADMINISTRATIVE EXPENSES	TOTAL
Wages and salaries.....	451,255	464,499	20,767	248,361	1,184,882
Share-based payments.....	133,486	505,715	18,602	131,589	789,392
Social security expenses.....	220,556	227,772	10,735	127,714	586,777
<b>Total Personnel expenses .....</b>	<b>805,297</b>	<b>1,197,986</b>	<b>50,104</b>	<b>507,664</b>	<b>2,561,051</b>

FOR THE SIX MONTH PERIOD ENDED JUNE 30, 2014 (Amounts in euros)	OTHER R&D EXPENSES	CLINICAL STUDIES	INTELLECTUAL PROPERTY	GENERAL AND ADMINISTRATIVE EXPENSES	TOTAL
Wages and salaries.....	323,675	173,678	21,268	435,332	953,953
Share-based payments.....	—	—	—	79,488	79,488
Social security expenses.....	136,724	76,301	11,394	167,391	391,810
<b>Total Personnel expenses .....</b>	<b>460,399</b>	<b>249,979</b>	<b>32,662</b>	<b>682,211</b>	<b>1,425,251</b>

As mentioned in the above paragraph “Major events of the period” the following warrants have been allocated during the period:

Allocation of BSA<sub>2012</sub> to independent members of the Board of Directors

The Board of Directors meeting held on April 29, 2015 granted 2,150 BSA<sub>2012</sub> to independent members of the Board of Directors. In accordance with IFRS 2, the Company performed a valuation of the BSA<sub>2012</sub> granted and used the Black-Scholes measurement model to perform this valuation.

The primary assumptions used to determine the fair value of the BSA<sub>2012</sub> allocated to senior management are:

- Risk-free rate: 0.07% (according to the zero coupon government bond rates curve);
- Expected dividends: 0%;
- Volatility: 20.5% based on the historical volatility observed on the NextBiotech index;
- Expected maturity: 2.5 years.

The fair value of the BSA<sub>2012</sub> was estimated at €512,010 and was fully recorded as of June 30, 2015 in the “other” caption of general and administrative expenses.

“2014 Plan”

In 2014, the Shareholders’ Meeting of the Company allocated 12,000 BSPCE<sub>2014</sub> to senior management. In accordance with IFRS 2, this allocation was valued during fiscal year 2014 due to the fact that all the conditions were met at that date, except for a service condition. Consequently, the fair value of this plan of €372,059 is recorded gradually over the duration of the 3-year plan in conformity with IFRS 2. For the six month period ending on June 30, 2015 an expense was recognized for an amount of €59,418 as personnel expenses. The Board of Directors meeting held on June 23, 2015 granted, in accordance with the conditions of the 2014 Plan, the following warrants:

- Completion of the allocation of the first tranche of the BSPCE<sub>2014</sub> to a category of employees with management status by identifying the beneficiaries of these warrants. 2,500 warrants were allocated. In accordance with IFRS 2, the Company performed a valuation of the BSPCE<sub>2014</sub> granted to these people and used the Black-Scholes measurement model to perform this valuation.

The primary assumptions used to determine the fair value of these BSPCE<sub>2014</sub> are:

- Risk-free rate: 0.27% according to the tranche (according to the zero coupon government bond rates curve);
- Expected dividends: 0%;
- Volatility: 20.75% based on the historical volatility observed on the NextBiotech index;
- Expected maturity: 4.3 years according to the tranche.

The fair value of the BSPCE<sub>2014</sub> was estimated at €516,735 and was fully recorded as of June 30, 2015 as personnel expenses split as follows: €424,758 for the research and development personnel costs and €91,977 for the general and administrative personnel costs.

Following the recruitment of Dr. El-Hariry and in accordance with Annex IV-BSA<sub>2014</sub> Regulations, all the conditions required to fully allocate the 3,000 BSA<sub>2014</sub> were met at the date of recruitment, with the exception of a service condition for tranche 2 and 3. In accordance with IFRS 2, the Company performed a valuation of the BSA<sub>2014</sub> granted to Dr. El-Hariry and used the Black-Scholes measurement model to perform this valuation.

The primary assumptions used to determine the fair value of these BSA<sub>2014</sub> are:

- Risk-free rate: between 0.27% and 0.45% according to the tranches (according to the zero coupon government bond rates curve);

- Expected dividends: 0%;
- Volatility: between 19.59% to 20.75% according to the tranches based on the historical volatility observed on the NextBiotech index;
- Expected maturity: between 4.3 and 5.3 years according to the tranches allocated.

The fair value of the BSA<sub>2014</sub> was estimated at €622,244. This expense will be recorded gradually over the duration of the 3-year plan in conformity with IFRS 2 (graded vesting method). An expense of €213,234 was recognized under personnel expenses (research and development personnel costs only), for the period ended June 30, 2015.

#### 4.4 Depreciation and amortization expenses

	<b>FOR THE SIX MONTH PERIOD ENDED JUNE 30,</b>	
	<b>2015</b>	<b>2014</b>
<b>(Amounts in euros)</b>		
Clinical studies.....	101,227	84,848
Research and development expenses .....	13,614	16,377
Intellectual property expenses.....	-	-
General and administrative expenses .....	18,122	12,720
<b>Total depreciation and amortization expenses .....</b>	<b>132,963</b>	<b>113,945</b>

#### 4.5 Financial income and expense

	<b>FOR THE SIX MONTH PERIOD ENDED JUNE 30</b>	
	<b>2015</b>	<b>2014</b>
<b>(Amounts in euros)</b>		
Interest on leases .....	(2,599)	(3,681)
Other finance expenses .....	(15,338)	(30,158)
<b>Total finance expense.....</b>	<b>(17,937)</b>	<b>(33,839)</b>
Income from short term investments .....	256,585	—
Other finance income .....	86,430	37,349
<b>Total finance income.....</b>	<b>343,015</b>	<b>37,349</b>
	<b>325,078</b>	<b>3,510</b>

Revenues from short-term investments correspond to accrued interest on term deposits as at June 30, 2015. Other financial incomes consist in foreign exchange gains recognized on June 30, 2015.

#### V. Notes related to the unaudited interim condensed consolidated statements of financial position

##### 5.1 Non-current assets

###### *Intangible assets*

For the six month period ended June 30, 2015, investments related to intangible assets correspond to the acquisition of software licenses.

###### *Property, plant and equipment*

The changes in the gross value of the property, plant and equipment are mainly due to the acquisition of office equipment and computers.

###### *Other non-current financial assets*

The other non-current financial assets correspond to the deposit paid for the leasing of the Boston office.

There are no new leasing agreements signed over the period.

## 5.2 Trade and other receivables

	AS OF	
	JUNE 30, 2015	DECEMBER 31, 2014
<b>(Amounts in euros)</b>		
Trade receivables .....	266,648	104,870
Other receivables .....	—	—
<b>Total trade and other receivables .....</b>	<b>266,648</b>	<b>104,870</b>

As the company does not sell its product candidates, the trade receivables relate exclusively to the re-invoicing of research and development expenses incurred for the AML clinical trial to Orphan Europe.

## 5.3 Other current assets

	AS OF	
	JUNE 30, 2015	DECEMBER 31, 2014
<b>(Amounts in euros)</b>		
Research Tax Credit.....	2,615,785	1,523,688
Tax receivables (VAT, etc.) and other receivables ....	551,623	494,271
Accruals and prepaid expenses .....	441,701	216,779
Other subsidies to be received .....	-	-
<b>Total .....</b>	<b>3,609,109</b>	<b>2,234,738</b>

The payment of the 2014 research tax credit amounting to €1,523,688 had not been received by the Company as of June 30, 2015. The research tax credit asset as of June 30, 2015 includes the balance for 2014 and 2015 research tax credit.

## 5.4 Cash and cash equivalents

	AS OF	
	JUNE 30, 2015	DECEMBER 31, 2014
<b>(Amounts in euros)</b>		
Cash and cash equivalents .....	31,046,421	36,988,436
<b>Total cash and cash equivalents as reported in statement of financial position .....</b>	<b>31,046,421</b>	<b>36,988,436</b>
Bank overdrafts.....	—	—
<b>Total cash and cash equivalents as reported in statement of cash flow .....</b>	<b>31,046,421</b>	<b>36,988,436</b>

At June 30, 2015, the cash position is composed of the following items: (i) €1.2 million in current accounts and (ii) €29.5 million in term deposits (available subject to an approximately 30-day notice).

At December 31, 2014, the cash position is composed of the following items: (i) €3.0 million in monetary UCITS, (ii) €1.9 million in current accounts and (iii) €32.0 million in term deposits (available subject to an approximately 30-day notice).

### 5.5 Shareholder's equity

At December 31, 2014, the share capital is composed of a total of 6,882,761 fully paid shares with a nominal value of €0.1 per share.

As the Company listed on NYSE Euronext on May 6, 2013, certain holders of BSPCE<sub>2012</sub> wanted to exercise BSPCE<sub>2012</sub> subscribed by them. On June 23, 2015, the Board of Directors, acting under the delegations of authority granted by the Extraordinary General Meeting held on 21 May 2012 and on the basis of a list provided by Société Générale, acting as securities registrar, noted that 6,530 new shares were fully subscribed and paid for a total amount of €48,073.86 with €653 corresponding to the nominal value of the shares and €47,420.86 to the premium.

The share capital was increased by a total amount of €653 from €688,276.10 to €688,929.10, divided into 6,889,291 shares with a nominal value of €0.1 each.

### 5.6 Long-term provisions

The long-term provisions are broken down as follows:

	AS OF	
	JUNE 30, 2015	DECEMBER 31, 2014
<b>(Amounts in euros)</b>		
Provision for retirement indemnities.....	91,946	88,594
Provisions for litigations.....	-	-
<b>Total</b> .....	<b>91,946</b>	<b>88,594</b>

## 5.7 Financial liabilities

Financial liabilities by type

	AS OF	
	JUNE 30, 2015	DECEMBER 31, 2014
<b>(Amounts in euros)</b>		
<b>Financial liabilities</b>		
Financial liabilities related to leases .....	180,209	220,376
Bank overdrafts.....	-	-
Reimbursable advances.....	539,911	549,161
Convertible bonds .....	-	-
Other .....	81,000	-
<b>Total financial liabilities .....</b>	<b>801,119</b>	<b>769,119</b>

Maturity dates of financial liabilities as of June 30, 2015 are as follows:

	LESS THAN ONE YEAR	MORE THAN ONE YEAR	TOTAL
<b>(Amounts in euros)</b>			
<b>Financial liabilities</b>			
Loans			-
Conditional advances .....	508,250	31,661	539,911
Liabilities related to leases .....	67,410	112,798	180,208
Convertible bonds .....			-
Bank overdrafts .....			-
<b>Total financial liabilities.....</b>	<b>575,660</b>	<b>144,459</b>	<b>720,119</b>

Maturity dates of financial liabilities as December 31, 2014 are as follows:

	LESS THAN ONE YEAR	MORE THAN ONE YEAR	TOTAL
<b>(Amounts in euros)</b>			
<b>Financial liabilities</b>			
Loans			-
Conditional advances .....	257,500	291,661	549,161
Liabilities related to leases .....	76,002	144,374	220,376
Convertible bonds .....			-
Bank overdrafts .....			-
<b>Total financial liabilities.....</b>	<b>333,502</b>	<b>436,035</b>	<b>769,537</b>

## 5.8 Other current liabilities

	AS OF	
	JUNE 30, 2015	DECEMBER 31, 2014
<b>(Amounts in euros)</b>		
Taxation and social security.....	554,873	970,629
Deferred revenue	97,996	368,436
Other payables .....	80,115	500,593
<b>Total other current liabilities .....</b>	<b>732,983</b>	<b>1,839,658</b>

The Company was given notice in June 2015 to reimburse a subsidy received for the GR-SIL program from BPI France. The amount of the subsidy from inception is €81,000.

The dispute relates to ending of the program by the Company. BPI France considers that the Company has not fulfilled all its declarative requirements relating to this subsidy. The Company has requested further information from BPI France as it considers that the required declarations have been filed.

As of June 30, 2015, a provision of €81,000 has been recorded.

The taxation and social security costs decrease is related to bonuses and the social security charges for the senior management which were accrued as of December 31, 2014.

The decrease of the deferred revenue is mainly due to the subsidy received from BPI France for the TEDAC program. As of June 30, 2015 the Company incurred additional expenses which reduced the deferred revenue related to the subsidy.

The other payables are provisions for the invoices of the PANC 2013-03 program which were not received as at December 31, 2014.

## 5.9 Related parties

Gil Beyen and Yann Godfrin are senior executives of the Company; Jérôme Bailly is the Company's chief pharmacist. The other related parties are members of the board of directors.

There have been no significant changes since December 31, 2014 in the types of transaction undertaken with related parties.

The Company has no further related parties.

### 5.10 Financial instruments recorded in the unaudited interim condensed consolidated statements of financial

<u>AS OF JUNE 30, 2015</u>	CARRYING AMOUNT ON THE STATEMENT OF FINANCIAL POSITION	FAIR VALUE THROUGH P&L	LOANS AND RECEIVABLES	DEBT AT AMORTIZED COST	FAIR VALUE
<i>(Amounts in euros)</i>					
Non-current financial assets <sup>(1)</sup> .....	89,784		89,784		89,784
Other current assets <sup>(1)</sup> .....	3,609,109		3,609,109		3,609,109
Trade and other receivables .....	266,648		266,648		266,648
Cash and cash equivalents <sup>(2)</sup> .....	31,046,421	31,046,421			31,046,421
<b>Total financial assets</b> .....	<b>35,011,962</b>	<b>31,046,421</b>	<b>3,965,541</b>	—	<b>35,011,962</b>
Financial liabilities—Non-current portion <sup>(1)</sup> ..	144,459			144,459	144,459
Financial liabilities—Current portion <sup>(1)</sup> .....	575,660			575,660	575,660
Trade payables and related accounts <sup>(1)</sup> .....	3,840,222			3,840,222	3,840,222
<b>Total financial liabilities</b> .....	<b>4,560,341</b>	—	—	<b>4,560,341</b>	<b>4,560,341</b>

  

<u>AS OF DECEMBER 31, 2014</u>	CARRYING AMOUNT ON THE STATEMENT OF FINANCIAL POSITION	FAIR VALUE THROUGH P&L	LOANS AND RECEIVABLES	DEBT AT AMORTIZED COST	FAIR VALUE
<i>(Amounts in euros)</i>					
Non-current financial assets <sup>(1)</sup> .....	81,814		81,814		81,814
Other current assets <sup>(1)</sup> .....	2,234,738		2,234,738		2,234,738
Trade and other receivables .....	104,870		104,870		104,870
Cash and cash equivalents <sup>(2)</sup> .....	36,988,436	36,988,436			36,988,436
<b>Total financial assets</b> .....	<b>39,409,858</b>	<b>36,988,436</b>	<b>2,421,422</b>	—	<b>39,409,858</b>
Financial liabilities—Non-current portion <sup>(1)</sup> ..	436,035			436,035	436,035
Financial liabilities—Current portion <sup>(1)</sup> .....	333,502			333,502	333,502
Trade payables and related accounts <sup>(1)</sup> .....	2,084,546			2,084,546	2,084,546
<b>Total financial liabilities</b> .....	<b>2,854,083</b>	—	—	<b>2,854,083</b>	<b>2,854,083</b>

<sup>(1)</sup> The carrying amount of these assets and liabilities is a reasonable approximation of their fair value.

<sup>(2)</sup> Level 2 fair value

### 5.11 Off balance sheet commitments

There have been no significant changes since December 31, 2014. The company has no other off balance sheet commitments as compared to the year ended December 31, 2014.

### 5.12 Events after balance sheet date

The company announced on July 20, 2015 a positive DSMB safety review following the treatment of the first 24 patients with ERY-ASP in its Phase 2 study in pancreatic cancer.

### 5.13 Notes regarding the change in presentation of consolidated financial statements

As part of its initial public offering project in the United States on the Nasdaq, ERYTECH Pharma submitted half-year financial statements whose presentation differs from the historical presentation of

the financial statements previously filed with the AMF. For the sake of harmonization, the Company decided to apply the same presentation in the consolidated financial statements filed with the AMF. These changes relate exclusively to the presentation of net consolidated income statements and the consolidated cash flows.

#### **5.13.1 Consolidated statement of net income**

##### **a) Combination of research and development expenses**

All expenditures on R&D costs were combined as a single line item of the consolidated statement of net income. Detailed information is given in the notes.

##### **b) Removal of the aggregate "current operating income"**

The company had decided to present the aggregate "current operating income" in accordance with Recommendation CNC2009-R03 relating to the format of financial statements of companies under international accounting standards. This aggregate was removed.

There is no difference between current operating income and operating income historically presented in the financial statements filed with the AMF.

##### **c) Change in presentation of the net financial income**

The Company's net financial income presented the cost of net financial debt and other financial income and expenses. In the financial statements as at June 30, 2015, the net financial income has been broken down between financial expenses and financial income.

This change in presentation has no significant impact given the fact that the amount of financial expenses mainly correspond to the cost of net financial debt.

This treatment had not been applied for the interim financial statements as at June 30, 2014 previously submitted. The comparative information for the six months ended June 30, 2014 included in these financial statements has been restated. The restatements are presented below:

(amounts in euros)	<b>June 30, 2014 (6 months)</b>		<b>June 30, 2014 (6 months)</b>
	Non-restated		restated
Operating income		Operating income	
Other income	721,980	Other income	721,980
<b>Total Operating income</b>	<b>721,980</b>	<b>Total Operating income</b>	<b>721,980</b>
Research and development expenses	(940,719)		
Clinical trials	(766,993)	Research and development expenses	(1,913,985)
Intellectual property costs	(206,273)		
General and administrative expenses	(1,991,388)	General and administrative expenses	(1,991,388)
<b>Current operating loss</b>	<b>(3,183,393)</b>		
Other operating income and expenses			
<b>Operating loss</b>	<b>(3,183,393)</b>	Total operating	<b>(3,183,393)</b>
Cost of net financial debt	(29,781)	Financial income	37,349
Other income and financial expenses	33,292	Financial expenses	(33,839)
<b>Financial income</b>	<b>3,510</b>	<b>Financial income</b>	<b>3,510</b>
<b>Pre-tax income (loss)</b>	<b>(3,179,883)</b>	<b>Pre-tax income (loss)</b>	<b>(3,179,883)</b>
Income tax	(4,173)	Income tax	(4,173)
<b>Net loss</b>	<b>(3,184,056)</b>	<b>Net loss</b>	<b>(3,184,056)</b>

#### 5.14 Consolidated cash flow

##### a) Change in presentation of operating grants

The Company decided to change the presentation of subsidies in the statement of cash flows in the financial statements to comply with the industry practice. They were previously presented as a deduction from net income in calculating the cash flow before financial income and taxes, they are now presented in the change in operating working capital (change in other current assets).

This change in presentation has no impact on the amount of net cash flows from operating activities.

##### b) Change in presentation of cost of net financial debt

The Company decided to present the gross amount of interest expense in the cash flow statements. The impact with the historical presentation is not significant.

##### c) Change in presentation of changes in working capital

The Company decided to break down the change in working capital in the financial statements to provide more detailed information for this position given its significant aspect.

##### d) Presentation of additional information

The Company decided to present the amount of interest paid as additional information to the cash flow statement.

The impact of these changes in presentation is not significant to the amount of different captions of cash flows (operating, investing and financing).

This treatment had not been applied for the interim financial statements as at June 30, 2014 previously submitted. The comparative information for the six months ended June 30, 2014 presented in these financial statements has been restated. The restatements are presented below:

(amounts in euro)	June 30, 2014 Non-restated	(amounts in euro)	June 30, 2014 Restated
<b>Net loss</b>	<b>(3,184,056)</b>	<b>Net loss</b>	<b>(3,184,056)</b>
Expenses (income) with non-cash impact		Expenses (income) with non-cash impact	
- Amortization and depreciation	113,945	Amortization and depreciation	113,945
- Increase in long-term provisions	25,196	Increase in long-term provisions	25,196
- Expense related to share-based payments	79,488	Expense related to share-based payments	79,488
- part of subsidies transferred to income	-		
- Gain or losses on disposal of assets	-		
Subsidies	(707,266)		
Cost of net financial debt	(29,781)	Interest expense	25,750
Income tax (current and deferred)	4,173	Income tax (current and deferred)	4,173
Operating cash flow before financial income and tax	(3,638,739)	Operating cash flow before change in working capital	(2,935,504)
Tax paid	-		
		Change in inventory	(21,645)
		Change in trade receivables and related accounts	(19,622)
		Change in other current assets	(305,357)
		Change in suppliers and related accounts	18,958
		Change in other current liabilities	(654,062)
<b>Change in working capital</b>	<b>336,252</b>	<b>Change in working capital</b>	<b>(371,014)</b>
<b>Net cash flow used in operating activities</b>	<b>(3,302,486)</b>	<b>Net cash flow used in operating activities</b>	<b>(3,306,518)</b>
<b>Cash flows from investing activities</b>		<b>Cash flows from investing activities</b>	
Acquisition of assets	(163,117)	Acquisition of assets	(163,117)
Intangible assets	(8,777)	Intangible assets	(8,777)
Property, plant and equipment	(154,340)	Property, plant and equipment	(154,340)
Financial assets	-	Financial assets	-
Disposal of assets	1,197	Disposal of assets	1,197
Intangible assets	-	Intangible assets	-
Property, plant and equipment	-	Property, plant and equipment	-
Financial assets	1,197	Financial assets	1,197
<b>Net cash flow used in investing activities</b>	<b>(161,919)</b>	<b>Net cash flow used in investing activities</b>	<b>(161,919)</b>
Cash flows from financing activities		Cash flows from financing activities	
Capital increases	56,098	Capital increases	56,098
Transaction costs	-	Transaction costs	-
Proceeds from borrowings	-	Proceeds from borrowings	-
Repayment of borrowings	(63,641)	Repayment of borrowings	(63,641)
Treasury shares	648,980	Treasury shares	648,980
Cash paid for interests	(4,031)		
<b>Net cash flow from financing activities</b>	<b>637,407</b>	<b>Net cash flow from financing activities</b>	<b>641,437</b>
<b>Changes in cash and cash equivalents</b>	<b>(2,827,000)</b>	<b>Changes in cash and cash equivalents</b>	<b>(2,827,000)</b>
Cash and cash equivalents at the beginning of the period	15,112,523	Cash and cash equivalents at the beginning of the period	15,112,523
Cash and cash equivalents at the close of the period	12,285,523	Cash and cash equivalents at the close of the period	12,285,523
<b>Changes in net cash and cash equivalents</b>	<b>(2,827,000)</b>	<b>Changes in net cash and cash equivalents</b>	<b>(2,827,000)</b>
		<b>Supplemental disclosure of cash flows information</b>	
		Cash paid for interest	7,738

## V. STATUTORY AUDITORS' REPORT ON THE INTERIM FINANCIAL STATEMENTS

*(Free translation of a French language original)*

### **Erytech Pharma S.A.**

Headquarters : 60, avenue Rockefeller – 69008 Lyon

Share capital : €690,164.10

### **Statutory auditors' report on the interim financial information as of June 30, 2015**

Six month period ended June 30, 2015

In fulfillment of the assignment that was entrusted to us by your general meeting and in accordance with article L.451-1-2 III of French *Code monétaire et financier*, we hereby report to you on:

- the review on the accompanying interim condensed consolidated financial statements of the Company Erytech Pharma S.A., relating to the six month period ended June 30, 2015;
- the verifications of the information included in the half-year activity report.

These interim condensed consolidated financial statements are the responsibility of the Board of Directors. Our responsibility is to express a conclusion on these financial statements based on our review.

#### **I- Conclusion on the financial statements**

We conducted our review in accordance with professional standards applicable in France. A review consists primarily of making inquiries of persons responsible for financial and accounting matters and applying analytical procedures. A review is substantially less in scope than an audit conducted in accordance with professional standards applicable in France and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit..

Based on our review, nothing has come to our attention that causes us to believe that the accompanying consolidated financial statements are not prepared in conformity with IAS 34 - standard of the IFRSs as adopted by the European Union applicable to interim financial information.

#### **II- Specific verifications**

We also verified the information provided in the interim activity report commenting the interim condensed consolidated financial statements subject of our limited review. We have no observations to formulate regarding their fair presentation and consistency with the interim condensed consolidated financial statements.

*(French original signed by)*

*Lyon, September 25, 2015*

*KPMG Audit Rhône Alpes Auvergne*

Sara Righenzi de Villers  
*Commissaire aux comptes*

*Lyon, September 25, 2015*

*RSM CCI Conseils*

Gaël Dhalluin  
*Associé*

**VI. CERTIFICATION BY THE PERSON RESPONSIBLE FOR THE HALF-YEAR FINANCIAL REPORT AS OF JUNE 30, 2015**

"I hereby certify that, to my knowledge, the financial statements for the six-month period ended June 30, 2015 were prepared in accordance with applicable accounting principles and give a true and fair view of the assets and liabilities, and of the financial position and results of the Company, and that the half-year activity report attached includes a true and fair presentation of major events that occurred during the first six months of the financial year and their impact on the financial statements, the significant transactions with related parties and a description of the main risks and uncertainties mentioned in paragraph II.E for the remaining six months of the year."

Lyon, September 25, 2015

**Gil BEYEN**

**Chairman and Chief Executive Officer**